Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)

Background: Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations. Methods: We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis. Results: The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI < 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI < 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged ≥65 years, confirming the drug’s utility in the elderly. Safety was consistent with previous reports, with no new signals detected. Conclusions: Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.

Authors

Institutions

Publication Details

Journal
Pharmacy
Published
2026-04-24
DOI
https://doi.org/10.3390/pharmacy14030063
Primary Topic
Psoriasis: Treatment and Pathogenesis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)

P Herranz, G. Carretero, Raquel Rivera, Salvador Arias et al.
Pharmacy
Psoriasis: Treatment and Pathogenesis
article

Real-World Effectiveness and Safety of Tildrakizumab in a Large Spanish Multicenter Cohort from Spanish Psoriasis Group (GPS)

P Herranz, G. Carretero, Raquel Rivera, Salvador Arias, Francisco Javier García‐Latasa, Javier Mataix, A. Mateu, E. del Alcázar, Pablo de la Cueva, N Eiris, Alvaro Gónzalez-Cantero, Anna López-Ferrer, Isabel Belinchon, Sergio Santos, Mar Llamas-Velasco, Diana Ruiz-Genao, Jose-María Carrascosa, Antonio Sahuquillo, Lourdes Rodriguez Fernández-Freire, Laura Salgado-Boquete, Ricardo Ruíz-Villaverde, Marta Ferran
article en

Abstract

Background: Tildrakizumab, an anti-IL-23p19 monoclonal antibody, has demonstrated efficacy in clinical trials, but real-world evidence remains crucial for confirming its profile in diverse populations. Methods: We have conducted a multicenter, retrospective observational study within the Spanish Psoriasis Group (GPS). This study updates previous findings with a larger sample size (n = 372) and longer follow-up. We assessed absolute Psoriasis Area and Severity Index (PASI), Body Surface Area (BSA), and the Dermatology Life Quality Index (DLQI) improvements, as well as safety, in patients with moderate-to-severe plaque psoriasis. Results: The cohort included a large population of patients with a high prevalence of comorbidities and prior biologic exposure. Effectiveness was high, with a significant proportion of patients achieving PASI < 1. Compared to recent real-world data, our cohort demonstrates superior complete clearance rates (PASI < 1) and includes a comprehensive DLQI assessment. Notably, 79 patients were aged ≥65 years, confirming the drug’s utility in the elderly. Safety was consistent with previous reports, with no new signals detected. Conclusions: Tildrakizumab shows robust effectiveness and safety in a complex, bio-experienced real-world population. The lack of clinical predictors of response suggests a need for future pharmacogenetic exploration.

PharmacyVol. 14(3)
Universitat de Miguel Hernández d'Elx (ES), Universidad Francisco de Vitoria (ES), Hospital Universitario La Paz (ES), Hospital de Sant Pau (ES), Hospital Universitario Virgen Macarena (ES), Hospital Universitario de Gran Canaria Doctor Negrín (ES), Hospital Universitario Fundación Alcorcón (ES), Hospital Universitario 12 De Octubre (ES), Hospital Royo Villanova (ES), Instituto de Investigación Biosanitaria de Granada (ES), Hospital Universitario Virgen de las Nieves (ES), Hospital Universitario Doctor Peset (ES), Instituto Ramón y Cajal de Investigación Sanitaria (ES), Hospital Universitario de La Princesa (ES), Hospital Del Mar (ES), Hospital Universitario Central de Asturias (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Universitari Germans Trias i Pujol (ES), Hospital Marina Baixa (ES), Hospital Virgen de los Lirios (ES), Complejo Hospitalario de Pontevedra (ES), Hospital Universitario Infanta Leonor (ES), Universidad Autónoma de Madrid (ES)
Responsible consumption and production
Openalex Percentile: Top 10%
Psoriasis: Treatment and Pathogenesis
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.